Novel therapies for rheumatoid arthritis

Pathophysiology

Volumn 12, Issue 3, 2005, Pages 217-225

  Chang, James ^a   Kavanaugh, Arthur ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Biologic agents; Cytokine; Rheumatoid arthritis; Therapy; Tumor necrosis factor (TNF)

Indexed keywords

ADALIMUMAB; AMG 714; ANTIINFLAMMATORY AGENT; ATLIZUMAB; BIOLOGICAL FACTOR; CYTOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; IMMUNOLOGIC AGENT; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 TRAP; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ANTAGONIST; INTERLEUKIN 18; INTERLEUKIN 18 ANTIBODY; INTERLEUKIN 18 BINDING PROTEIN; INTERLEUKIN 1BETA CONVERTING ENZYME INHIBITOR; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; LEA 29 Y; METHOTREXATE; PRALNACASAN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG;

B LYMPHOCYTE; CLINICAL TRIAL; DISEASE ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; HUMAN; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; INFECTION; INFECTION RISK; INFLAMMATION; INJECTION SITE REACTION; LIVER TOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE; TREATMENT OUTCOME;

EID: 25444464091     PISSN: 09284680     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pathophys.2005.07.008     Document Type: Article

References (98)

1. M.C. Hochberg, and T.D. Spector Epidemiology of rheumatoid arthritis: update Epidemiol. Rev. 12 1990 247 252
2. E.D. Harris Jr., R.C. Budd, and G.S. Firestien 7th ed. Kelley's Textbook of Rheumatology vol. 2 2005 Elsevier Saunders Philadelphia
3. D. Dougados, T. Suurmeiher, and B. Krol Work disability in early rheumatoid arthritis Ann. Rheum. Dis. 54 1995 445 460
4. D.M. Mitchell, P.W. Spitz, and D.Y. Yound Survival, prognosis and causes of death in rheumatoid arthritis Arthritis Rheum. 29 1986 706 714
5. D.A. Fox The role of T cells in the immunopathogenesis of rheumatoid arthritis: new perspectives Arthritis Rheum. 40 1997 598 609
6. M. Feldmann, F.M. Brennan, and R.N. Maini Rheum. Arthritis Cell 85 1996 307 310
7. D.T. Felson, J.J. Anderson, and M. Boers The American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis Arthritis Rheum. 38 1995 727 735
8. J.F. Fries, P.W. Spitz, and D.Y. Young The dimensions of health outcomes: the health assessment questionnaire, disability, and pain scales J. Rheumatol. 20 1993 557 560
9. A. Larsen, K. Dale, and M. Eek Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films Acta Radiol. Diagn. 18 1977 481 491
10. T.J. Sharp, M.D. Lidsky, and L.C. Collins Methods of scoring the progression of radiographic changes in rheumatoid arthritis: correlation of radiographic, clinical, and laboratory abnormalities Arthritis Rheum. 14 1971 706 720
11. G.S. Firestein Evolving concepts of rheumatoid arthritis Nature 423 2003 356 361
12. T. Saxne, M.A. Palladino Jr., D. Heinegärd, N. Talal, and F.A. Wollheim Detection of tumor necrosis factor α but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum Arthritis Rheum. 31 2003 1041 1045
13. I.C. Chikanza, G. Kingsley, and G.S. Panayi Peripheral blood and synovial fluid monocyte expression of interleukin 1α and 1β during active rheumatoid arthritis J. Rheumatol. 22 1995 600 606
14. A.M. Bendele, E.S. Chlipala, and J. Scherrer Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis Arthritis Rheum. 43 2000 2648 2659
15. R.A. Black, C.T. Rauch, and C.J. Kozlosky A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells Nature 385 1997 729 733
16. E.H. Choy, and G.S. Panayi Cytokine pathways and joint inflammation in rheumatoid arthritis New Engl. J. Med. 344 2001 907 916
17. D.R. Bertolini, G.E. Nedwin, T.S. Bringman, D.D. Smith, and G.R. Mundy Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors Nature 319 1986 516 518
18. R.N. Maini, E.W. St. Clair, F. Breedveld, D. Furst, J. Kalden, and M. Weisman Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase II trial Lancet 354 1999 1932 1939
19. P.E. Lipsky, D.M.F.M. van der Heijde, and E.W. St. Clair Infliximab and methotrexate in the treatment of rheumatoid arthritis New Engl. J. Med. 343 2000 1594 1602
20. J. Smolen, D. van der Heijde, and P. Emery Infliximab inhibits radiographic joint damage in patients with early rheumatoid arthritis regardless of clinical response after 54 weeks treatment Ann. Rheum. Dis. 63 Suppl. I 2004 260
21. M.E. Weinblatt, J.M. Kremer, A.D. Bankhurst, K.J. Bulpitt, R.M. Fleischmann, and R.I. Rox A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate New Engl. J. Med. 340 1999 253 259
22. L.W. Moreland, M.H. Schiff, S.W. Baumgartner, E.A. Tindall, R.M. Fleischmann, and K.J. Bulpitt Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial Ann. Intern. Med. 130 1999 478 486
23. J.M. Bathon, R. Martin, R.M. Fleischmann, J.R. Tesser, M.H. Schiff, and E.C. Keystone A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis N Engl. J. Med. 343 2000 1586 1593
24. M.C. Genovese, J.M. Bathon, R.W. Martin, R.M. Fleischmann, J.R. Tesser, and M.H. Schiff Etanercept versus methotrexate in patients with early rheumatoid arthritis two year radiographic and clinical outcomes Arthritis Rheum. 46 2002 1443 1450
25. M.E. Weinblatt, E.C. Keystone, D.E. Furst, L.W. Moreland, M.H. Weisman, and C.A. Birbara Adalimumab, a fully human monoclonal antibody for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial Arthritis Rheum. 48 2003 35 45
26. E. Keystone, A. Kavanaugh, J. Sharp, H. Tennenbaum, Y. Hua, L. Teoh, S. Fischkoff, and E. Chartash Radiographic, clinical, and functional outcomes with adalimumab (a human anti-TNF alpha monoclonal antibody) in the treatment of patients with active rheumatoid arthritis on concomitant methorexate theapy: a randomized, controlled 52 week-trial Arthritis Rheum. 50 2004 1400 1411
27. L. Klareskog, D. van der Heijde, and J.P. de Jager Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial Lancet 363 2004 675 681
28. A. Kavanaugh, and E. Keystone The safety of biologic agents in early rheumatoid arthritis Clin. Exp. Rheumatol. 21 Suppl. 31 2003 71 76
29. R.C. Newton, K.A. Solomon, and M.B. Covington Biology of TACE inhibition Ann. Rheum. Dis. 60 Suppl. III 2001 25 32
30. K.A. Bush, J.S. Walker, and J. Frazier Effects of a PEGylated soluble TNF receptor type 1 (PEG s TNF-R1) on cytokine expression in adjuvant arthritis Scand. J. Rheumatol. 31 2002 198 204
31. J.A. Eastgate, J.A. Symons, and N.C. Wood Correlation of plasma interleukin 1 levels with disease activity in rheumatoid arthritis Lancet 2 8613 1988 706 709
32. C.A. Dinarello Biologic basis for interleukin-1 in disease Blood 87 1993 2095 2147
33. J.E. Sims, M.A. Gayle, and J.L. Slack Interleukin-1 signaling occurs exclusively via the type I receptor Proc. Natl. Acad. Sci. USA 90 1993 6155 6159
34. J.M. Dayer The pivotal role of interleukin-1 in the clinical manifestations of rheumatoid arthritis Rheumatology 42 Suppl. 2 2003 ii3 ii10
35. R. Horai, S. Saijo, and H. Tanioka Development of chronic inflammatory arthroplasty resembling rheumatoid arthritis in interleukin 1 receptor antagonist deficient mice J. Exp. Med. 191 2 2000 313 320
36. W.B. van den Berg Uncoupling of inflammatory and destructive mechanisms in arthritis Semin. Arthritis Rheum. 30 5 Suppl. 2 2001 7 16
37. B. Bresnihan, J.M. Alvaro-Garcia, and M. Cobby Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist Arthritis Rheum. 41 12 1998 2196 2204
38. S. Cohen, E. Hurd, and J. Cush Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four week, multicenter, randomized, double-blind, placebo-controlled trial Arthritis Rheum. 46 3 2002 614 624
39. Y. Jiang, H.K. Genant, and I. Watt A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores Arthritis Rheum. 43 2000 1001 1009
40. G. Nuki, B. Bresnihan, and M.B. Bear Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized double-blind, placebo-controlled trial Arthritis Rheum. 46 11 2002 2838 2846
41. M. Genovese, S. Cohen, and L. Moreland A randomized double blind controlled study evaluating the safety and efficacy of etanercept versus etanercept plus anakinra in patients with rheumatoid arthritis Ann. Rheum. Dis. 62 Suppl. 1 2003 66
42. A.M. Bendele, E.S. Chlipala, and J. Scherrer Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models with rheumatoid arthritis Arthritis Rheum. 43 12 2000 2648 2659
43. A.N. Economides, L.R. Carpenter, and J.S. Rudge Cytokine traps: multi-componenet, high-affinity blockers of cytokine action Nat. Med. 9 2003 47 52
44. Regeneron reports phase II results for IL-1 trap clinical program in rheumatoid arthritis: IL-1 trap phase II study demonstrates clinical activity and favorable safety and tolerability profile, 2003, http://www.regeneron.com/ investor/press_detail.asp?v_c_id=184.
45. G. Ku, T. Faust, and L.L. Lauffer Interleukin-1β converting enzyme inhibition blocks progression of Type II collagen-induced arthritis in mice Cytokine 8 1996 377 386
46. Aventis and vertex pharmaceuticals voluntarily discontinue phase IIb clinical trials of pralnacasan in rheumatoid arthritis: phase II activities temporarily suspended while unexpected toxicology results analysed, 2003, http://www.vpharm.com/Pressreleases2003/pr111003av.html.
47. C.R. Flannery, C.B. Little, C.E. Hughes, C.L. Curtis, B. Caterson, and S.A. Jones IL-6 and its soluble receptor augment aggrecanase-mediated proteoglycan catabolism in articular cartilage Matrix Biol. 19 2000 549 553
48. H. Isshiki, S. Akira, T. Sugita, Y. Nishio, S. Hashimoto, and T. Pawlowski Reciprocal expression of NF-IL6 and C/EBP in hepatocytes: possible involvement of NF-IL6 in acute phase protein gene expression New Biol. 3 1991 63 70
49. J. Bravo, and J.K. Heath Receptor recognition by gp130 cytokines EMBO J. 19 2000 2399 2411
50. M. Brozik, I. Rosztoczy, K. Meretey, G. Balint, M. Gaal, and Z. Balogh Interleukin 6 levels in synovial fluids of patients with different arthritides: correlation with local IgM rheumatoid factor and systemic acute phase protein production J. Rheumatol. 19 1992 63 68
51. B. Dasgupta, M. Corkill, B. Kirkham, T. Gibson, and G. Panayi Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis J. Rheumatol. 19 1992 22 25
52. S. Kotake, K. Sato, K.J. Kim, N. Takahashi, N. Udagawa, and I. Nakamura Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation J. Bone Miner. Res. 11 1996 88 95
53. A. Boe, M. Baiocchi, M. Carbonatto, R. Papoian, and O. Serlupi-Crescenzi Interleukin 6 knock-out mice are resistant to antigen-induced experimental arthritis Eur. Cytokine Netw. 11 1999 1057 1064
54. N. Takagi, M. Mihara, Y. Moriya, N. Nishimoto, K. Yoshizaki, and T. Kishimoto Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis Arthritis Rheum. 41 1998 2117 2121
55. M. Mihara, M. Kotoh, N. Nishimoto, Y. Oda, E. Kumagai, and N. Takagi Humanized antibody to human interleukin-6 receptor inhibits the development of collagen arthritis in cynomolgus monkeys Clin. Immunol. 98 2001 319 326
56. E.H. Choy, D.A. Isenberg, T. Garrood, S. Farrow, Y. Ioannou, and H. Bird Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial Arthritis Rheum. 46 2002 3143 3150
57. N. Nishimoto, K. Nakahara, and T. Kishimoto Anti-interleukin-6 receptor antibody therapy normalizes serum vascular endotherial growth factor (VEGF) in patients with rheumatoid arthritis (RA) Arthritis Rheum. 46 Suppl. 2002 250
58. R. Maini Charisma Study Group. A double-blind, randomised, parallel group, controlled, dose ranging study of the safety, tolerability, pharmacokinetics and efficacy of repeat doses of MRA given alone or in combination with methotrexate in patients with rheumatoid arthritis Ann. Rheum. Dis. 62 Suppl. 2003 64
59. I.B. McInnes, and J.A. Gracie Interleukin-15: a new cytokine target for the treatment of inflammatory diseases Curr. Opin. Pharmacol. 4 2004 392 397
60. I. Gonzalez-Alvaro, A.M. Ortiz, and R. Garcia-Vicuna Increased serum levels of interleukin-15 in rheumatoid arthritis with long-term disease Clin. Exp. Rheumatol. 21 2003 639 642
61. S. Kotake, H.R. Schumacher Jr., and C.H. Yarboro In vivo gene expression of type 1 and type 2 cytokines in synovial tissues from patients in early stages of rheumatoid, reactive, and undifferentiated arthritis Proc. Assoc. Am. Phys. 109 1997 286
62. F.Y. Liew, and I.B. McInnes Role of interleukin 15 and interleukin 18 in inflammatory response Ann. Rheum. Dis. 61 Suppl. 2 2002 ii100 ii102
63. H. Ruchatz, B.P. Leung, and X. Wei Soluble IL-15 receptor alpha-chain administration prevents murine collagen-induced arthritis: a role for IL-15 in development of antigen-induced immunopathology J. Immunol. 160 1998 5654 5660
64. S. Ferrari-Lacraz, E. Zanelli, and M. Neuberg Targeting IL-15 receptor-bearing cells with an antagonist mutant IL-15/Fc protein prevents disease development and progression in murine collagen-induced arthritis J. Immunol. 173 2004 5818 5826
65. I.B. McInnes, R. Martin, I. Zimmerman-Gorska, et al. Safety and efficacy of a human monoclonal antibody to IL-15 (AMG 714) in patients with rheumatoid arthritis: results from a multicenter, randomized, double-blind, placebo-controlled trial, in: Proceedings of the 68th Annual Scientific Meeting of American College of Rheumatology, San Antonio, Texas, 2004, abstract 527.
66. A.J. Puren, G. Fantuzzi, Y. Gu, M.S.-S. Su, and C.A. Dinarello Interleukin-18 (IFNγ-inducing factor) induces IL-8 and IL-1β via TNFα production from non-CD14+ human blood mononuclear cells J. Clin. Invest. 101 1998 711 724
67. T. Ghayur, S. Bannerjee, and M. Hugunin Caspase-1 processes IFN-gamma-inducing factor and regulates LPS-induced IFN-gamma production Nature 386 1997 619 623
68. L.A. Joosten, T.R. Radstake, and E. Lubberts Association of interleukin-18 expression with enhanced levels of both interleukin-1 beta and tumor necrosis factor alpha in knee synovial tissue of patients with rheumatoid arthritis Arthritis Rheum. 48 2003 339 347
69. J.A. Gracie, R.J. Forsey, W.L. Chan, A. Gilmour, B.P. Leung, and M.R. Greer A proinflammatory role for IL-18 in rheumatoid arthritis J. Clin. Invest. 104 1999 1393 1401
70. X.Q. Wei, B.P. Leung, H.M. Arthur, I.B. McInnes, and F.Y. Liew Reduced incidence and severity of collagen-induced arthritis in mice lacking IL-18 J. Immunol. 166 2001 517 521
71. R.L. Smeets, F.A. van de Loo, O.J. Arntz, M.B. Bennink, L.A. Joosten, and W.B. van den Berg Adenoviral delivery of IL-18 binding protein C ameliorates collagen-induced arthritis in mice Gene Ther. 10 2003 1004 1011
72. C. Plater-Zyberk, L.A. Joosten, M.M. Helsen, P. Sattonnet-Roche, C. Siegfried, and S. Alouani Therapeutic effect of neutralizing endogenous IL-18 activity in the collagen-induced model of arthritis J. Clin. Invest. 108 2001 1825 1832
73. J.J. Cush, and P.E. Lipsky Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis Arthritis Rheum. 31 1988 1230 1238
74. P. Stastny Association of the B-cell alloantigen DRw4 with rheumatoid arthritis New Engl. J. Med. 298 1978 869 871
75. L. Koulova, E.A. Clark, G. Shu, and B. Dupont The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells J. Exp. Med. 173 1991 759 762
76. P.S. Linsley, J.L. Greene, W. Brady, J. Bajorath, J.A. Ledbetter, and R. Peach Human B7-1 (CD80) and B7-2 (CD86) bind with similar avidities but distinct kinetics to CD28 and CTLA-4 receptors Immunity 1 1994 793 801
77. P. Tan, C. Anasetti, J.A. Hansen, J. Melrose, M. Brunvand, and J. Bradshaw Induction of alloantigen-specific hyporesponsiveness in human T lymphocytes by blocking interaction of CD28 with its natural ligand B7/BB1 J. Exp. Med. 177 1993 165 173
78. J. Verwilghen, R. Lovis, and M. De Boer Expression of functional B7 and CTLA4 on rheumatoid synovial T cells J. Immunol. 153 1994 1378 1385
79. G.L. Warner, Exploratory repeat-dose intravenous efficacy study in cynomolgus monkeys, study 94648. Bristol-Myers Squibb Pharmaceutical Research Institute Report No. 51377, 1995.
80. L.M.C. Webb, M.J. Walmsley, and M. Feldmann Prevention and amelioration of collagen-induced arthritis by blockade of the CD28 co-stimulatory pathway: requirement for both B7-1 and B7-2 Eur. J. Immunol. 26 1996 2320 2328
81. J.R. Abrams, M.G. Lebwohl, and C.A. Guzzo CTLA4Ig-mediated blockade of T-cell costimulation in patients with Psoriasis vulgaris J. Clin. Invest. 103 1999 1243 1252
82. J.R. Abrams, S.L. Kelley, and E. Hayes Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-iImmunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells J. Exp. Med. 192 2000 681 694
83. L.W. Moreland, R. Alten, F. Van den Bosch, T. Appelboom, M. Leon, and P. Emery Costimulatory blockade in patients with rheumatoid arthritis. A pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4 and LEA29Y eighty-five days after the first infusion Arthritis Rheum. 46 2002 1470 1479
84. J.M. Kremer, R. Westhovens, M. Leon, E. Di Giorgio, A. Rieke, and S. Steinfeld CTLA4Ig: co-stimulatory blockade in the treatment of rheumatoid arthritis New Engl. J. Med. 349 1907-1915
85. E. Keystone, J. Sibilia, S. Steinfeld, et al., Efficacy of abatacept (CTLA4Ig; BMS-188667) in combination with methotrexate in the treatment of early and established rheumatoid arthritis. EULAR 2004, Berlin, Germany (Abstract OP0104).
86. C.W. Weyand, P.J. Kurtin, and J.J. Goronzy Ectopic lymphoid organogenesis: a fast track for autoimmunity Am J. Pathol. 159 2001 787 793
87. R.E. Schrohenloher, S.L. Bridges Jr., and W.J. Koopman Rheumatoid factor WJ. Koopman Arthritis and Allied Conditions: A Textbook of Rheumatology 13th ed. 1997 Williams and Wilkins Baltimore 1109 1130
88. D. van Zeben, J.M. Hazes, and A.H. Zwinderman Clinical significance of rheumatoid factors in early rheumatoid arthritis: results of a follow up study Ann. Rheum. Dis. 51 1992 1029 1035
89. D. Baeten, I. Peene, and A. Union Specific presence of intracellular citrullinated proteins in rheumatoid arthritis synovium: relevance to antifilaggrin autoantibodies Arthritis Rheum. 44 2001 2255 2262
90. F.A. van Gaalen, S.P. Linn-Rasker, and W.J. van Venrooij Autoantibodies to cyclic citrullinated peptides predict progression to rheumatoid arthritis in patients with undifferentiated arthritis: a prospective cohort study Arthritis Rheum. 50 2004 709 715
91. T. Dorner, and G.R. Burmester The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets Curr. Opin. Rheumatol. 15 2003 246 252
92. O.T. Chan, L.G. Hannum, and A.M. Haberman A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus J. Exp. Med. 189 1999 1639 1648
93. S. Takemura, P.A. Klimiuk, and A. Braun T cell activation in rheumatoid synovium is B cell dependent J. Immunol. 167 2001 4710 4718
94. J.C. Edwards, M.J. Leandro, and G. Cambridge B lymphocyte depletion therapy with rituximab in rheumatoid arthritis Rheum. Dis. Clin. N Am. 30 2004 393 403
95. J.C. Edwards, and G. Cambridge Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology 40 2001 205 211
96. M.J. Leandro, J.C. Edwards, and G. Cambridge Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann. Rheum. Dis. 61 2002 883 888
97. S. De Vita, F. Zaja, and S. Sacco Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells Arthritis Rheum. 46 2002 2029 2033
98. J.C. Edwards, L. Szczepanski, and J. Szechinski Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis N Engl. J. Med. 350 2004 2572 2581